Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia

HAO-CHIEN WANGDjajalaksana, SusanthySusanthyDjajalaksanaSharma, LathaLathaSharmaTheerakittikul, TheerakornTheerakornTheerakittikulLim, Hui FangHui FangLimYoo, Kwang HaKwang HaYooYu-Lin, Andrea BanAndrea BanYu-LinDiaz, Dina VDina VDiazYang, LalaLalaYangBeekman, Maarten J H IMaarten J H IBeekman2023-12-042023-12-042023-101939-4551https://scholars.lib.ntu.edu.tw/handle/123456789/637496The extent of short-acting Beta-2-agonist (β2-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia.enAdrenergic beta-2 receptor agonists; Asia; Asthma; Prescriptions; Public healthEvaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asiajournal article10.1016/j.waojou.2023.100823378695602-s2.0-85174185710https://api.elsevier.com/content/abstract/scopus_id/85174185710